Expanded Hemodialysis Using a Medium Cut-Off Dialyzer for Severe Valproic Acid Poisoning: A Case Report with Real-Time Therapeutic Drug Monitoring.
This case suggests that intermittent hemodialysis with a medium cut-off dialyzer can effectively reduce valproic acid levels in severe poisoning cases, but further studies are needed to confirm these findings.
Where it sits
this study against the rest of the l-carnitine (levocarnitine) corpusSummary and findings
This case report details the management of a 54-year-old woman with severe valproic acid (VPA) poisoning using intermittent hemodialysis with a medium cut-off dialyzer. Initial plasma VPA levels were 262.99 µg/mL, which decreased to 141.48 µg/mL at 2 hours and 97.81 µg/mL at 4 hours, indicating a reduction of 62.8%. The patient showed improvement in consciousness and was discharged with normalized VPA levels.
Abstract
<b>Background:</b> Valproic acid (VPA) poisoning has a dynamic clinical course and may require extracorporeal toxin removal (ECTR) in severe cases. Intermittent hemodialysis is the preferred ECTR technique; however, clinical experience with expanded hemodialysis (HDx) using medium cut-off (MCO) membranes in acute VPA intoxication is scarce. We describe a case of severe VPA poisoning managed with intermittent HDx and outline the clinical rationale and kinetic response. <b>Case Report:</b> A 54-year-old woman presented to the emergency department after accidental presumably ingesting approximately 4 g of VPA, with depressed consciousness (Glasgow Coma Scale 7) and metabolic acidosis (pH 7.10, HCO<sub>3</sub><sup>-</sup> 13 mmol/L, PCO<sub>2</sub> 50 mmHg, lactate 2.8 mmol/L, ionized calcium 0.8 mmol/L, elevated anion gap). Initial plasma VPA was 262.99 µg/mL, ammonia was 14 µmol/L, and cranial computed tomography showed no acute abnormalities. ECTR was initiated in the intensive care unit as intermittent HDx using an MCO dialyzer for 4 h. Serial VPA concentrations were obtained before treatment, at 2 h, and at the end of the session to guide real-time prescription adjustment, with an increase in blood flow from 200 to 230 mL/min. <b>Results:</b> VPA decreased from 262.99 µg/mL pre-HD to 141.48 µg/mL at 2 h (46.2% reduction) and 97.81 µg/mL at 4 h (62.8% reduction), with clear improvement in the level of consciousness. A mild post-dialysis rebound was observed (100.07 µg/mL at 14 h). The patient recovered without additional ECTR and was discharged with normalized VPA levels on follow-up. <b>Conclusions:</b> In this patient, intermittent HDx with an MCO membrane was feasible, well tolerated, and associated with rapid VPA clearance and neurological recovery. Serial drug monitoring enabled bedside optimization of the dialysis prescription and post-treatment evaluation. A single HDx session was sufficient, and VPA therapy was safely reintroduced under close monitoring.
Background
This paper addresses the clinical management of severe valproic acid poisoning, a critical condition that can lead to significant morbidity. Prior knowledge indicates that traditional hemodialysis may not be sufficient for effective removal of certain toxins. The use of a medium cut-off dialyzer represents an innovative approach that may enhance toxin clearance.
Methods
The study is a case report that details the application of expanded hemodialysis in a single patient. Specific details regarding the patient population, n, dose, duration, and route of administration are not provided in the abstract. The primary outcome appears to involve therapeutic drug monitoring.
Results
Not reported in abstract.
Interpretation
Given that this is a case report, the findings cannot be generalized to a broader population. The lack of detailed numeric findings limits the ability to assess the clinical significance of the intervention. The absence of a control group and reliance on a single case raises concerns about the robustness of the conclusions.
Key findings
- Not reported in abstract.
Limitations
- Case report, limiting generalizability.
- No numeric findings reported.
- Single patient experience.
- Not a controlled study.